These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15882278)

  • 21. Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?
    Macdougall IC
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii18-21. PubMed ID: 16079325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
    Macdougall IC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pure red cell aplasia secondary to treatment with erythropoietin.
    Locatelli F; Del Vecchio L
    J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge.
    Smalling R; Foote M; Molineux G; Swanson SJ; Elliott S
    Biotechnol Annu Rev; 2004; 10():237-50. PubMed ID: 15504708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.
    Lim SK; Bee PC; Keng TC; Chong YB
    Clin Nephrol; 2013 Sep; 80(3):227-30. PubMed ID: 23298519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients.
    Kharagjitsingh AV; Korevaar JC; Vandenbroucke JP; Boeschoten EW; Krediet RT; Daha MR; Dekker FW;
    Kidney Int; 2005 Sep; 68(3):1215-22. PubMed ID: 16105053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eprex-associated pure red cell aplasia and leachates.
    Schellekens H; Jiskoot W
    Nat Biotechnol; 2006 Jun; 24(6):613-4. PubMed ID: 16763579
    [No Abstract]   [Full Text] [Related]  

  • 28. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.
    Shimizu H; Saitoh T; Ota F; Jimbo T; Tsukada Y; Murakami H; Nojima Y
    Acta Haematol; 2011; 126(2):114-8. PubMed ID: 21654161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.
    Verhelst D; Rossert J; Casadevall N; Krüger A; Eckardt KU; Macdougall IC
    Lancet; 2004 May; 363(9423):1768-71. PubMed ID: 15172775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Eprex in Canada.
    Légaré C; Turner C; Klein AV
    CMAJ; 2004 Sep; 171(6):552-3. PubMed ID: 15367446
    [No Abstract]   [Full Text] [Related]  

  • 31. Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study.
    Patsialas S; Fowler H; Guilatco R; Salts S; Xia FR; Gomez Perez S; Iwanowitsch A; Kohnle M
    Clin Nephrol; 2023 May; 99(5):247-255. PubMed ID: 36871229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.
    Asari A; Gokal R
    J Am Soc Nephrol; 2004 Aug; 15(8):2204-7. PubMed ID: 15284306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia.
    Praditpornsilpa K; Tiranathanakul K; Jootar S; Tungsanga K; Eiam-Ong S
    Clin Nephrol; 2014 May; 81(5):355-8. PubMed ID: 23110772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epoetin-β induced pure red cell aplasia: an unintended consequence.
    Javaid MM; Khatri P; Subramanian S
    Postgrad Med J; 2017 Mar; 93(1097):168-169. PubMed ID: 27932518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].
    Janda K; Kraśniak A; Krzanowski M; Sułowicz W
    Przegl Lek; 2010; 67(3):187-91. PubMed ID: 20687383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic mechanisms of EPO-associated pure red cell aplasia.
    Schellekens H
    Best Pract Res Clin Haematol; 2005; 18(3):473-80. PubMed ID: 15792922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
    Fijal B; Ricci D; Vercammen E; Palmer PA; Fotiou F; Fife D; Lindholm A; Broderick E; Francke S; Wu X; Colaianne J; Cohen N
    Pharmacogenomics; 2008 Feb; 9(2):157-67. PubMed ID: 18370845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
    Evens AM; Bennett CL; Luminari S
    Best Pract Res Clin Haematol; 2005; 18(3):481-9. PubMed ID: 15792923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience.
    Carracedo J; Madueño JA; Ramirez R; Martin-Malo A; de Francisco AL; Aljama P;
    J Nephrol; 2005; 18(4):382-7. PubMed ID: 16245241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A simple screening test for the detection of erythropoietin antibodies.
    Meran S; Wonnacott A; Davies M; Ellis R; Phillips A
    Clin Nephrol; 2014 Sep; 82(3):215-20. PubMed ID: 23391321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.